BMO Capital Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform on Takeover
Tweet
Share
E-mailGet Alerts ASPX Hot Sheet
Price: $100.96 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
BMO Capital downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform after the company agreed to be acquired by Teva Pharmaceuticals this morning.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $70.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
- Deutsche Bank Downgrades Rheinmetall AG (RHM:GR) (RNMBY) to Hold
- Barclays Downgrades SSAB AB (SSABB:SS) (SSAAY) to Equalweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
